Learn More
  • Dena Lyras, Jennifer R. O’Connor, Pauline M. Howarth, Susan P. Sambol, Glen P. Carter, Tongted Phumoonna +6 others
  • 2009
Clostridium difficile is the leading cause of infectious diarrhoea in hospitals worldwide, because of its virulence, spore-forming ability and persistence. C. difficile-associated diseases are induced by antibiotic treatment or disruption of the normal gastrointestinal flora. Recently, morbidity and mortality resulting from C. difficile-associated diseases(More)
  • Michael A. Jhung, Angela D. Thompson, George E. Killgore, Walter E. Zukowski, Glenn Songer, Michael Warny +4 others
  • 2008
Clostridium difficile is a recognized pathogen in neonatal pigs and may contribute to enteritis in calves. Toxinotype V strains have been rare causes of human C. difficile-associated disease (CDAD). We examined toxinotype V in human disease, the genetic relationship of animal and human toxinotype V strains, and in vitro toxin production of these strains.(More)
Our study sought to compare the strain types of Clostridium difficile causing initial and recurrent episodes of C. difficile infection (CDI) in adult patients with a first episode of CDI or 1 prior episode of CDI within the previous 90 days. Strains originated from patients who had been entered into two phase 3 randomized clinical trials of fidaxomicin(More)
Introduction Clostridium difficile is a human and animal pathogen causing intestinal infections following disturbance of the gut microbiota, usually as a result of prior antibiotic treatment. Since the discovery of C. difficile as the major cause of pseudomembranous colitis (PMC), pathogenesis has been linked to production of toxins and two large, single(More)
Several different nomenclatures have been applied to the Clostridium difficile toxins and their associated genes. This paper summarizes the new nomenclature that has been agreed to by the research groups currently active in the field. The revised nomenclature includes C. difficile toxins and other related large clostridial toxins produced by Clostridium(More)
Recent reports of reduced response to standard therapies for Clostridium difficile infection (CDI) and the risk for recurrent CDI that is common with all currently available treatment agents have posed a significant challenge to clinicians. Current recommendations include metronidazole for treatment of mild to moderate CDI and vancomycin for severe CDI.(More)
Reports of fidaxomicin treatment for patients with multiple recurrent Clostridium difficile infections ([mrCDI] ie, more than 2 CDI episodes) indicate symptomatic response to this agent, but 50% have subsequent mrCDI episodes. In an effort to improve outcomes in patients with mrCDI we used novel regimens of fidaxomicin based on strategies used with(More)
  • Robert H. Cowie, James R. Hollyer, Alexandre J. da Silva, Robert G. Hollingsworth, Marlena C. Dixon, Praphathip Eamsobhana +26 others
  • 2012
In a concluding session of the workshop, the participants developed a list of 115 research and outreach needs, outlining the top 5-7 needs in each of 8 areas (Table). For complete information, including presenter details and abstracts, visit the workshop website at www.hawaii.edu/cowielab/Angio%20website%20home.htm.